EyePoint
EyePoint Pharmaceuticals Inc is an American clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of serious ocular diseases, prominently featuring its proprietary Durasert bioerodible technology platform for sustained intraocular drug delivery. The company develops sustained-release treatments for back-of-the-eye diseases, including wet age-related macular degeneration and diabetic macular edema. Its core business activities encompass biopharmaceutical research, drug formulation design, clinical trial execution, and commercial healthcare marketing. As a biotechnology enterprise advancing clinical pipelines, the company generates revenue through commercial sales of existing products like Yutiq and Dexycu, alongside pharmaceutical partnership agreements. EyePoint Pharmaceuticals holds a leading market position in sustained-release ocular drug delivery. The company is headquartered in Watertown, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in EyePoint.
- Legal name
- EyePoint Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding EyePoint
- Schroder ISF Healthcare Innovation — Schroders · 0.39 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.33 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)